Chong Xu

Chong Xu has been involved in various roles in the healthcare industry since 2015. In that year, they became a Board Observer for Eyebright Medical Technology, Yisheng Group, and F-Prime Capital, where they also held the role of Partner, investing in and incubating early-stage healthcare startups. In 2017, they became a Board Observer for Semma Therapeutics and in 2019, they became a Board Observer for Sironax and Co-Founder, Investor, and Board Director for Geneception (Shanghai) Bio-technology Co.,Ltd. / Skyline Therapeutics. Chong was also a Board Director for Citrine Medicine / RareStone Group and Board Observer for LenoMed in 2020, and a Director Board of Directors for K36 Therapeutics, Inc. and Adagene in 2021.

Chong Xu obtained a Bachelor of Science in Biological Sciences&Technology from Zhejiang University, followed by a Master of Business Administration (MBA) in Business Administration and Management, General from the University of Virginia Darden School of Business. Chong then pursued a Ph.D. in Cell Biology from the University of Virginia, and completed a Visiting Student program at the Institute of Molecular Agrobiology of the National University of Singapore.